Drug intelligence / Profile preview

AM-510

Development stage: Preclinical
Lead developer: Aion Medicines

Overview

AM-510 is an early-stage drug candidate currently in the discovery phase, developed by Aion Medicines for the treatment of Opioid Use Disorder (OUD). As of early 2024, specific details regarding its molecular target, mechanism of action, and modality have not been publicly disclosed by the developer. The program is part of Aion Medicines' strategic focus on addressing high unmet medical needs in metabolic and neurological conditions.

Targets

KRAS (Kirsten rat sarcoma viral oncogene homolog)

Beyond the preview

Go deeper on AM-510.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AM-510.

Explore the full profile